Clinical Trials on Urinary Bladder Squamous Cell Carcinoma in Belgium

Total 877 results

University Hospital, Ghent
Algemeen Ziekenhuis Maria Middelares; AZ Sint-Lucas Gent; AZ Jan Palfijn Gent

Not yet recruiting

Diversity in Patients With OAB (DOAB)

Overactive Bladder | Sacral Neuromodulation | Diversity | Onabotulinum Toxin A | Discrete Choice Experiment

Belgium
Astellas Pharma Europe B.V.
Veeda Clinical Research

Completed

Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome) (VENICE)

Lower Urinary Tract Predominant Storage Symptoms

Belgium
University Hospital, Ghent

Terminated

A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis

Squamous Cell Carcinoma of the Oral Cavity | Oropharynx Metastases | Lymph Metastases

Belgium
Pfizer

Terminated

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | Carcinoma, Squamous Cell | Carcinoma, Large Cell | Carcinoma, Adenosquamous Cell

United States, Bulgaria, Italy, Spain, Ukraine, Belgium, France, Ireland, Korea, Republic of, Poland, Russian Federation, United Kingdom, Hungary, Serbia, Taiwan, Canada, South Africa, Brazil, Romania, Greece, Puerto Rico, Czech Republic and more
Eli Lilly and Company

Withdrawn

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Metastatic Squamous Non-Small Cell Lung Cancer | Locally Advanced Squamous Non-Small Cell Lung Cancer

Italy, Romania, Germany, Belgium, Russian Federation, United States, United Kingdom
Universiteit Antwerpen
Amsterdam UMC, location VUmc; Novosanis NV; Self-screen B.V.

Completed

CASUS: Validation for Detection of Precursor Lesions (CASUS-WP4)

Cervical Cancer | Cervical Intraepithelial Neoplasia | HPV-Related Cervical Carcinoma | Urine | Human Papilloma Virus

Belgium
National Multiple Sclerosis Center

Terminated

Prospective Trial Comparing Intravesical Chondroitin Sulphate 2% and DMSO in the Treatment of PBS/Interstitial Cystitis

Interstitial Cystitis | Painful Bladder Syndrome

Belgium
University Hospital, Ghent

Completed

Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect.

Carcinoma, Renal Cell

Belgium
Cliniques universitaires Saint-Luc- Université...

Completed

A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy

Transitional Cell Carcinoma

Belgium
Astellas Pharma Inc

Completed

Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder

Overactive Bladder | Neurogenic Detrusor Overactivity

Belgium, Canada, Denmark, Netherlands, Poland, Turkey, United Kingdom
Jules Bordet Institute
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) (AURA)

Non-metastatic Muscle Invasive Bladder Cancer

France, Belgium
SOTIO Biotech AG
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

Hepatocellular Carcinoma | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Castration-resistant Prostate Cancer | Cutaneous Squamous Cell Carcinoma

Italy, Spain, France, Belgium, Czechia, United States, Poland, Georgia, Hungary
Pfizer

Completed

Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer

Neurogenic Detrusor Overactivity

Belgium
Allergan

Completed

A Research Study for Patients With Overactive Bladder

Overactive Bladder | Urinary Incontinence

Poland, Germany, United States, Canada, United Kingdom, Belgium
Astellas Pharma Inc

Completed

Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents

Urinary Bladder, Overactive

Sweden, United Kingdom, Belgium, Denmark
UNICANCER
Hoffmann-La Roche

Active, not recruiting

Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients (ALBAN)

Bladder Cancer

Spain, France, Belgium
University of Zurich

Recruiting

Bladder and TranscUtaneous Tibial Nerve Stimulation for nEurogenic Lower Urinary Tract Dysfunction (bTUNED)

Neurogenic Bladder Dysfunction

Belgium, Brazil, Italy, Switzerland
Cliniques universitaires Saint-Luc- Université...

Terminated

Efficacy of SU 011248 in Head And Neck Carcinoma

Recurrent Disease | Squamous Cell Head and Neck Carcinoma | Palliative Treatment

France, Belgium
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
University Hospital, Ghent

Recruiting

RCT Treatment Versus Non Treatment of Low-risk BCCs in Elderly (BASINEL)

Elderly | Basal Cell Carcinoma

Belgium
Universitaire Ziekenhuizen KU Leuven
KU Leuven

Recruiting

Prospective Sample Collection for Cancer of Bladder (ProCaB)

Urinary Bladder Neoplasms

Belgium
European Organisation for Research and Treatment...

Terminated

Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer

Bladder Cancer

Netherlands, Belgium, Italy, Turkey, Slovakia
Allergan

Completed

Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Overactive Bladder

Poland, United Kingdom, Belgium, Russian Federation, Czech Republic, Germany, United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130)

Carcinoma, Non-Squamous Non-Small Cell Lung

United States, Israel, Belgium, Canada, Spain, Germany, Italy, France
MedtronicNeuro

Terminated

Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder (ACCEPTANCE)

Urinary Incontinence | Detrusor Overactivity | Neurogenic Overactive Bladder

Belgium, France, United Kingdom, Germany, Italy, Netherlands
AZ-VUB
Sanofi

Unknown

Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Carcinoma

Belgium
Hoffmann-La Roche

Completed

An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy (TIME)

Non-Squamous Non-Small Cell Lung Cancer

Belgium
Universiteit Antwerpen

Recruiting

Comparison of a Paper and Automated Bladder Diary in Pediatric Patients

Overactive Bladder | Lower Urinary Tract Symptoms | Enuresis | Voiding Disorders

Belgium
European Organisation for Research and Treatment...

Completed

BCG With or Without Mitomycin in Treating Patients With Bladder Cancer

Bladder Cancer

Netherlands, Belgium, United Kingdom, Italy, Portugal, Turkey
Allergan

Completed

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Overactive Bladder

United Kingdom, Belgium, New Zealand, France, Russian Federation, Czech Republic, United States, Germany, Austria, Poland, Slovakia, Ukraine, Canada, Australia
Groupe Oncologie Radiotherapie Tete et Cou
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (TPEx)

Squamous Cell Head and Neck Carcinoma | Recurrent or Metastatic Disease

France, Belgium
Astellas Pharma Europe B.V.

Completed

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

Pediatric | Neurogenic Detrusor Overactivity

United States, Belgium, Korea, Republic of, Philippines, Poland, United Kingdom
AZ-VUB

Unknown

Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma.

Non Small Cell Lung Carcinoma

Belgium
AstraZeneca

Completed

Study of Tremelimumab in Patients With Advanced Solid Tumors

Pancreatic Ductal Adenocarcinoma | Triple-negative Breast Cancer | Urothelial Bladder Cancer

United States, Belgium, Korea, Republic of, Poland, Netherlands
AstraZeneca

Active, not recruiting

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer (POTOMAC)

Non-muscle-invasive Bladder Cancer

France, Spain, Belgium, Canada, Poland, Germany, Japan, Russian Federation, United Kingdom, Austria, Australia, Netherlands
Boehringer Ingelheim

Completed

Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder

Bladder, Neurogenic

Belgium, Spain, United States, India, South Africa, Philippines, Italy, Korea, Republic of, Russian Federation, Germany, Brazil, Mexico, Ukraine
Jules Bordet Institute

Completed

The Jules Bordet Institute Molecular Profiling Program Feasibility Trial (PRECISION-F)

Metastatic Melanoma | Colorectal Cancer Metastatic | Metastatic Non-Small Cell Lung Carcinoma

Belgium
Allergan

Completed

Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Overactive Bladder | Urinary Incontinence

Poland, United Kingdom, Belgium, Canada, Russian Federation, United States, Germany, Czechia
Allergan

Completed

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

Overactive Bladder | Urinary Incontinence

Poland, United Kingdom, Germany, Canada, Belgium, United States, Czechia
Universitaire Ziekenhuizen KU Leuven

Completed

Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients

Hiv | Human Papilloma Virus | Organ Transplants

Belgium
Novartis Pharmaceuticals

Terminated

Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

Squamous Non-small Cell Lung Cancer

Germany, Spain, Korea, Republic of, Belgium, Italy, United States, France, Sweden
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (SunRISe-5)

Non-Muscle Invasive Bladder Neoplasms

Korea, Republic of, United States, Argentina, Belgium, Brazil, China, Poland, United Kingdom, Italy, Japan, Germany, Romania
Ipsen

Terminated

Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder

Overactive Bladder

United Kingdom, Spain, Netherlands, Belgium, France, Germany, Czechia, Italy
Boehringer Ingelheim

Completed

PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder

Bladder, Neurogenic

Belgium, Spain, United States, South Africa, Philippines, Italy, Korea, Republic of, Russian Federation, Germany, India, Brazil, Canada, Mexico, Ukraine
European Lung Cancer Working Party

Completed

Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer

Non Small Cell Lung Carcinoma

Belgium
Hoffmann-La Roche

Completed

A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC) (MERIT)

Non-Squamous Non-Small Cell Lung Cancer

Hong Kong, Spain, Russian Federation, France, Bulgaria, Germany, Estonia, Italy, Poland, Taiwan, United Kingdom, Singapore, Ireland, Belgium
University Hospital, Antwerp
Universiteit Antwerpen; Belgian Cancer Registry

Enrolling by invitation

Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan (ZORALCS)

Smoking Cessation | Lung Cancer | Lung Cancer, Nonsmall Cell | Lung Cancer, Small Cell

Belgium
Universitair Ziekenhuis Brussel

Unknown

Risk-adapted Stereotactic Body Radiotherapy for Early Non-Small Cell Lung Cancer Using the VERO Stereotactic Body Radio Therapy System

Non-Small Cell Lung Carcinoma

Belgium
Slabbaert Koen

Unknown

Transvaginal Treatment of Symptomatic Cystocele Grade II-III (BCR)

Cystocele

Belgium
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

Urinary Bladder Neoplasms

United States, Belgium, Korea, Republic of, Germany, Italy, France, Spain, Canada, United Kingdom, Greece, Japan, Australia, Netherlands, Portugal, Russian Federation, Ukraine

Clinical Trials on Urinary Bladder Squamous Cell Carcinoma in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations